4D Molecular Therapeutics (FDMT) Receivables (2019 - 2022)

4D Molecular Therapeutics (FDMT) has 4 years of Receivables data on file, last reported at $700000.0 in Q4 2022.

• On a quarterly basis, Receivables fell 6.29% year-over-year to $700000.0 in Q4 2022; TTM through Dec 2022 was $700000.0, a 6.29% decrease from a year earlier, with the FY2022 full-year figure at $700000.0, down 6.29% from the prior year.
• Receivables for Q4 2022 stood at $700000.0, down from $747000.0 in the prior quarter.
• Over the last five years, Receivables for FDMT reached as high as $1.2 million in Q2 2021 and fell as low as $561000.0 in Q1 2021.
• Historically, Receivables has averaged $869428.6 across 4 years, with a median of $800000.0 in 2021.
• Across the five-year window, Receivables grew 12.47% in 2020 and plunged 32.09% in 2021, its largest moves.
• Year by year, Receivables stood at $978000.0 in 2019, then grew by 12.47% to $1.1 million in 2020, then plunged by 32.09% to $747000.0 in 2021, then dropped by 6.29% to $700000.0 in 2022.
• Per Business Quant data, the three most recent Receivables figures were $700000.0 in Q4 2022, $747000.0 in Q4 2021, and $800000.0 in Q3 2021.